

Drugs to Enhance Motor Recovery After Stroke

Steven C. Cramer, MD

Among the therapeutic strategies under study to improve long-term outcome after stroke are drugs targeting events that underlie recovery. Drugs that enhance recovery are separate from those that promote neuroprotection or reperfusion in patients with stroke. Recovery-based drugs have distinct therapeutic targets that are related to plasticity and growth after stroke, and in general, improvements in behavioral outcome are not accompanied by a reduction in infarct volume. Interventions targeting recovery have a time window measured in days or sometimes weeks-months, suggesting potential utility for a large percentage of patients with stroke. Currently, among drugs that enhance motor recovery after stroke in humans, the strongest evidence exists for serotonergic and dopaminergic agents. Restorative therapies generally target the brain directly, in contrast to approved stroke therapeutics that target arteries, clots, platelets, glucose, or cholesterol. Targeting the brain has wide-ranging implications, for example, in relation to drug delivery. In addition, because restorative drugs aim to change brain structure and function, their effects are influenced by concomitant behavioral experience, a finding that informs selection of entry criteria, outcome measures, and biomarkers in a clinical trial setting. These points underscore the importance of a neural systems approach in studying stroke recovery.

A new stroke activates several biological pathways, including those related to the ischemic cascade, immunologic response, and restorative response. These constitute distinct therapeutic targets for stroke therapy. Reperfusion therapies are effective when given during the early hours after stroke onset, when regions of ischemic penumbra remain salvageable. As a result of this narrow therapeutic time window, a minority of patients with stroke currently receives a reperfusion-based therapy acutely after stroke. Restorative therapies have a much wider time window, some being introduced during the days-weeks of spontaneous growth seen in the brain after stroke, and others introduced months later in an effort to stimulate neuroplasticity. Because of this wider time window, a large fraction of patients with stroke could potentially be eligible to receive a restorative therapy.

The current review focuses on drugs, specifically small molecules, which are commonly used in neurological practice and which have advantages compared with some treatment approaches in terms of drug delivery and access to the

brain.¹ Many types of restorative therapy besides small drugs are under study, including large molecules, such as growth factors or monoclonal antibodies, and biological agents, such as stem cells, brain stimulation, robotics, and activity-based therapies²; ultimately the value of any drug must be measured in relation to the risk/benefit performance of all candidate restorative therapies. The current focus is on a monotherapy approach, but increasing evidence will likely foster studies evaluating polytherapy approaches.

The current review is focused on the motor system. A systems approach is central to many aspects of restorative neuroscience. The brain is in many ways an amalgam of many different systems operating in parallel. For a stent retriever placed in the middle cerebral artery, the therapeutic target is a hemisphere full of at-risk brain systems. For a restorative therapy, however, only one or a few neural systems are likely to be viable therapeutic targets because many systems may be either decimated beyond repair or little affected. Adoption of a systems-level approach has immediate implications for clinical trials in relation to topics such as entry criteria, end points, biomarkers, and the concomitant training that is important for shaping the effects of a restorative therapy.

The current focus on the motor system reflects the fact that motor deficits are common after stroke (82% of patients³) and are linked with reduced quality of life.^{4,5} At 6 months after stroke, 65% of patients are unable to incorporate a paretic hand effectively into daily activities,⁶ which affects subjective well-being.⁷ Moreover, even when neurological examination declares the patient wholly recovered, 71% of patients report persistent motor deficits when studied using patient-reported outcomes.⁸ Lower extremity motor status is also linked with disability level.⁹ Only 37% of persons with stroke can walk after the first week poststroke, after which gait improvement is linked to better quality of life. Hemiplegic patients rank recovery of gait as their top priority.^{10,11}

Current Status

There are no drugs approved in the United States to enhance motor recovery after stroke.

However, the recent approval by the US Food and Drug Administration of a 4-aminopyridine preparation as a treatment to improve walking in patients with multiple sclerosis¹² sounds a hopeful note for stroke.

Received March 9, 2015; final revision received July 11, 2015; accepted July 15, 2015.

From the Departments of Neurology, Anatomy & Neurobiology, and Physical Medicine & Rehabilitation, University of California, Irvine, CA.

Correspondence to Steven C. Cramer, MD, UC Irvine Medical Center, 200 S Manchester Ave, Suite 206, Orange, CA 92868. E-mail scramer@uci.edu (*Stroke*. 2015;46:2998-3005. DOI: 10.1161/STROKEAHA.115.007433.)

© 2015 American Heart Association, Inc.

Stroke is available at <http://stroke.ahajournals.org>

DOI: 10.1161/STROKEAHA.115.007433

Drugs With Strongest Evidence to Date

For at least 2 classes of drug, serotonergic and dopaminergic, both of which are monoaminergic, existing evidence from human studies supports the possibility for enhancing motor outcome after stroke.

Serotonergic Drugs

Serotonin normally plays a role in modulating multiple cognitive functions, particularly response inhibition and memory consolidation, and modulates the impact of punishment-related signals on learning and emotion.^{13–15} Recent reports suggest potential clinical utility of selective serotonin reuptake inhibitor (SSRI) drugs for promoting improved motor outcome after stroke. Building on several prior smaller studies,^{16–19} the Fluoxetine for Motor Recovery After Acute Ischemic Stroke (FLAME) study²⁰ was a double-blind, placebo-controlled trial that enrolled nondepressed hemiplegic/hemiparetic patients within 10 days of ischemic stroke onset. Patients were randomized to 3 months of oral fluoxetine (20 mg/d) or placebo. Patients randomized to fluoxetine showed significantly greater gains on the primary end point, change in the arm/leg Fugl–Meyer motor score to day 90 ($P=0.003$), a remarkable difference of 9.7 points on this 100-point scale. Other human trials have reported favorable effects of SSRI drugs on recovery of nonmotor behaviors after stroke,^{21–23} increasing confidence in the results of the FLAME study. The importance of these findings is underscored by the substantial clinical experience with SSRI drugs (hundreds of millions of humans have been treated) and their generally strong safety record in the broad population, as well as in patients with cerebrovascular disease.^{24,25}

Several different mechanisms might account for these findings. The central mechanism of action for SSRI drugs in the treatment of major depression is via their high affinity for the serotonin transporter; drug binding to the transporter inhibits serotonin removal from the synaptic cleft, with long-term SSRI administration downregulating and desensitizing key serotonin receptors, thereby dampening negative feedback on serotonin release.²⁶ While it is true that the FLAME study excluded subjects with depression, these SSRI mechanisms might nonetheless have contributed to the findings in the FLAME study. Although depression is often classified dichotomously, that is, as present or absent, evidence suggests that depressive symptoms affect brain function along a continuum, with increasing levels of depressive symptoms associated with larger effects even when restricting analysis to subjects who do not meet criteria for major depression,^{27,28} including those after stroke.^{29,30} Consistent with this, better functional recovery after stroke is associated with lower depressive symptoms and with greater improvement of depressive symptoms over time.³¹

Other suggested mechanisms of action for SSRI drugs include reducing neural inflammation,³² enhancing neurotrophin activity,³³ and increasing neurogenesis.³⁴ Chronic SSRI dosing increases intracortical facilitation³⁵ and reduces intracortical inhibition,³⁶ and these changes have been compared with reinstating conditions of developmental critical periods.^{36,37} In addition, serotonin modulates spinal motor control through multiple effects on spinal motor circuits, including regulation of rhythmic activity and control of excitability,

by acting on intrasynaptic and extrasynaptic receptors; this may help locomotor function but can also worsen spasticity.³⁸

Dopaminergic Drugs

Dopamine regulates many aspects of neural functioning, including excitability, synaptic transmission, plasticity, protein trafficking, and gene transcription.³⁹ Not surprisingly, therefore, dopamine has a key role in wide-ranging brain processes, such as movement, reward, learning, and plasticity.⁴⁰ The role of this neurotransmitter in movement is well established: dopaminergic terminals in motor cortex contribute to cortical plasticity and indeed are necessary for motor skill learning.^{41,42} A randomized, double-blind, placebo-controlled study of 53 patients within 6 months of stroke onset found that 100 mg L-Dopa/day, given as Sinemet and combined with physical therapy, was significantly better than placebo plus physical therapy on motor recovery after 3 weeks, measured using the Rivermead Motor Assessment.⁴³ These effects were likely attributable to dopamine because studies in rodents, subhuman primates, and humans indicate that systemic administration of L-Dopa increases the brain concentration of dopamine but not norepinephrine—dopamine is the predominant brain metabolite formed from systemic L-Dopa.^{44–47}

Large studies of drugs that modulate dopamine neurotransmission after stroke continue to be needed, but lacking.⁴⁸ Smaller studies that have examined a range of dopaminergic drugs in patients with stroke at varying time points after onset have been inconsistent, with motor learning and plasticity improved in some studies⁴⁹ but not others.^{50–52} For example, a placebo-controlled, double-blind study of 33 patients 1 to 12 months after stroke did not find a difference between a 9-week course of ropinirole+physiotherapy compared with placebo+physiotherapy on gait velocity.⁵⁰ These differences might reflect small sample sizes. Some evidence suggests that genetic factors may be relatively important in modulating dopamine neurotransmission in humans.^{53–55}

Additional insight into divergent findings across studies of dopaminergic drugs might stem from the fact that a large number of environmental, cognitive, psychological, and other factors are important cofactors in the expression of dopamine effects. Dopamine is a central player in the limbic reward system, where, adding to the complexity, its neurotransmission is under the influence of numerous other transmitters.⁵⁶ Reward significantly influences long-term motor learning.⁵⁷ Dopamine is also important for motivation,⁵⁸ action learning,⁵⁹ action selection,⁶⁰ and in the control of voluntary exercise.⁶¹ Thus, as with serotonergic drugs, dopaminergic drugs might influence motor recovery after stroke indirectly, through their action on any of the several different nonmotor neural systems.

Other Drugs That Might Have Important Effects on Recovery

Noradrenergic Drugs

Noradrenergic neurotransmission broadly amplifies neuronal activity, increases the general level of excitability, and selectively amplifies activities evoked by unexpected inputs.⁶² This effect of norepinephrine on regulating overall arousal levels has a modulatory effect on executive function.¹⁴ To date, there has been only a handful of studies of noradrenergic drugs to

promote stroke recovery. These have been small in size, but show promising results.^{63–65}

Cholinergic Drugs

In the cortex, acetylcholine inputs positively enable plasticity by (1) selectively amplifying only anticipated (selectively attended) and (2) selectively weakening nonanticipated inputs.⁶² Modulation of nicotinic cholinergic neurotransmission alters attention, whereas muscarinic receptors play a greater role in cognitive flexibility.¹⁴ Luria long ago advocated for cholinergic therapies to enhance recovery,⁶⁶ yet few controlled studies in humans with stroke have been published to date. Limited data in nonmotor aspects of stroke recovery are promising,^{67–69} and a recent study in 33 patients found donepezil to be safe when initiated within 24 hours of stroke onset.⁶⁸

Amphetamine

Amphetamines increase neurotransmission in several monoamine systems. Initial studies of amphetamine to enhance poststroke motor^{70,71} or language⁷² recovery were small but promising. A subsequent randomized, double-blind, placebo-controlled trial of amphetamine in 71 patients with subacute stroke did not show a drug-related benefit.⁷³ At 5 to 10 days after stroke onset, patients were randomized to 10 sessions of either physiotherapy+amphetamine (10 mg) or physiotherapy+placebo, twice per week for 5 weeks. No difference between treatment groups was found for the primary outcome, Fugl–Meyer motor score. The subgroup with milder deficits might have derived the greatest drug-related gain, a possibility that requires further study. The optimal dose and administration schedule for amphetamine has not been rigorously studied, and it remains to be definitively evaluated in human patients with stroke.⁷⁴

Drugs That Impede Recovery

For several drugs, particularly neuroleptic or antiepileptic drugs, some evidence suggests that administration after stroke can impede motor recovery and thereby reduce motor outcome.^{75–78} Such findings could potentially provide insights into the mechanisms of stroke recovery and might also inform strategic planning in the design of pharmacological approaches to improving motor recovery after stroke.

Key Issues in Clinical Trials

Experiences such as those summarized above have identified several important issues in the design of clinical trials of brain repair after stroke.⁷⁹ These are considered below.

How Does Time Since Stroke Onset Affect a Restorative Therapy?

Time is a major factor. As with many central nervous system diseases, stroke evolves over time, and biological targets shift. The initial hyperacute injury period is followed by a several week period throughout which repair-related events spontaneously increase in the brain,^{80–82} and during which the brain is galvanized for growth in a manner resembling normal development.⁸³ A critical window for therapeutic effectiveness

has been defined during this period for several restorative interventions in preclinical studies.^{84–86} Drugs that promote recovery 1 week may be inert or even harmful the next.^{87–90} Importantly, because restorative therapies are generally introduced at a time when stroke injury is fixed, behavioral outcomes are improved after stroke without affecting final infarct volume. The period of spontaneous growth resolves over the ensuing weeks-months, but even in the chronic phase, clinically important gains may be seen for some therapies that aim to promote neural repair.^{91,92}

How Do a Patient's Activity, Training, and Experience After Stroke Affect a Restorative Therapy?

These are key considerations. When introducing a drug to promote plasticity after neural injury, the best behavioral recovery requires rehabilitation to mold new connections⁹³—neural repair after stroke occurs on the basis of experience-dependent plasticity.⁹⁴ In a landmark study, Feeney et al⁷⁵ found that in rodents with an experimental stroke, amphetamine improved motor outcome, but only if drug dosing was paired with training. Subsequent studies have confirmed this principle across many other classes of poststroke restorative therapy.^{95–99} This issue is not a consideration in acute stroke and preventative stroke studies, where treatment generally targets clots, platelets, arteries, the heart, or serum glucose or cholesterol levels. However, in stroke recovery studies, treatment often directly targets the brain, and retraining the brain is dependent on repeated behavioral reinforcement. Thus, the patient need not engage in any particular behavioral regimen to enable tissue-type plasminogen activator effectiveness, but available data indicate that such activity is central to realizing maximal effects of restorative drugs after stroke. These data are largely from preclinical studies, and so further studies in humans are needed to better understand the impact of poststroke activity and training as adjuvants to recovery drugs. Similarly, evidence suggests that the psychosocial milieu in which patients experience poststroke recovery is also a critically important experiential covariate.¹⁰⁰

Given These Many Influences on Stroke Recovery, How Can the Target Patient Population be Defined for a Drug Designed to Enhance Recovery After Stroke?

Several techniques show promise to identify target populations. Stroke is a heterogeneous condition. Just as no single drug is appropriate to treat all patients with cancer or pneumonia, so it is that no one therapy is likely to be useful to enhance recovery across all patients with stroke. Patients differ tremendously before the stroke, and infarcts are highly variable across subjects. Numerous measures have been studied for their ability to understand and to measure variance in behavioral recovery after stroke. Results have implications for patient selection and stratification in clinical trials of drugs targeting recovery. For example, in a study of 23 patients with chronic stroke undergoing robotic therapy to improve arm motor deficits, extent of stroke injury to the corticospinal tract accounted for approximately one third of the variance in treatment response.¹⁰¹ These results remain to be confirmed in a study using a drug to enhance motor recovery after stroke, but likely results will generalize across treatment categories. This is an example of an imaging-based approach

to identify the target population—extent of corticospinal tract injury substantially informs which patients are most likely to benefit from a recovery-based intervention. Further work remains to maximize the robustness of this approach, and this is a fervent area of investigation. Recent models emphasize an interaction between neural function and neural injury.^{102,103} For some therapies, including serotonergic^{104,105} and dopaminergic⁵³ drugs, measures of genetic variability might also inform the likelihood that a patient will benefit from a drug.

For some therapies, preclinical findings may provide specific guidance for defining the target human population. For example, in a phase III stroke trial of motor cortex stimulation, animal studies showing efficacy required preserved motor-evoked responses,^{98,106–108} but the trial¹⁰⁹ did not. A post hoc analysis found that trial enrollees randomized to epidural motor cortex stimulation who (like preclinical animals) had preserved motor-evoked responses were 2.5× more likely ($P < 0.05$) to achieve the primary efficacy end point as compared with enrollees lacking such responses.¹¹⁰

How Do These Issues Affect Selection of End Points in Trials of Drugs Aiming to Enhance Recovery After Stroke?

As noted earlier, a systems approach is often important to therapeutic studies of stroke recovery. A therapy that improves outcome by promoting neuroplasticity might have maximum effect in a neural system that has sustained subtotal injury, but show no effect in a system that has been utterly obliterated by stroke. As such, a restorative drug given to a patient with dense aphasia but moderate hemiparesis might provide useful gains in motor function but not in language function. In such a context, drug effects would likely be more apparent using an outcome measure that has the granularity to detect differential effects across neural systems of the brain.

These points suggest the potential utility of modality-specific outcome measures to capture effects of treatments that target stroke recovery.¹¹¹ Global end points that capture many aspects of human behavior and summarize a person's outcome using a single number (often a single digit) have established value in stroke clinical trials, but their value may be greatest for acute treatments that aim to salvage a large volume of threatened brain. On the other hand, for drugs that aim to enhance stroke recovery by improving function in specific neural systems that have been injured but survived, global end points might lack granularity and thus be insensitive; end points that are linked to the target neural system might provide a more accurate measure of drug effects. For example, a restorative therapy that significantly improves the modality-specific outcome measure gait velocity may or may not have a significant effect on the global outcome measure modified Rankin scale score, but improved gait might nonetheless be associated with improved quality of life¹¹² and social participation.¹¹³

How Do These Issues Affect Interpretation of Animal Models and Translation of Preclinical Stroke Recovery Studies?

The limits of preclinical models for stroke recovery remain to be completely defined. For studies focused on molecular responses to specific perturbations, rodent models offer great potential. Humans and rodents shared a common ancestor ≈80 to 100 million years ago. Most genes are shared, and

tissue-specific transcriptional responses have been highly conserved.^{114,115} However, as a human recovers during the weeks-months after a stroke, psychological issues, such as mood, hopelessness, resilience, anxiety, and caregiver support, may have important effects on outcomes, as might marital, religious, occupational, fiscal, litigational, and other social issues. Many patients at my institution struggle with insurance copayments, alcoholism, adjustments in retirement plans, power of attorney, and immigration status. Such factors of human life after stroke may be incompletely modeled in a study of rodents housed in an 18" cage with solitary (or single cellmate) confinement. A rat brain weighs 2 g, has one third the proportional white matter volume of a human brain, is perfused by a pulse >250 beats/min, and has had a distinct trajectory of psychosocial and cultural evolution since the common mammalian ancestor, as compared to humans.¹¹⁶ Thus, for studies focused on the net effect of a drug on behavioral recovery after stroke, rodent models may have critical limitations. Given that regulatory agencies emphasize the importance of clinically meaningful end points in human trials,¹¹⁷ rodent studies might be seen as providing the greatest insight at the molecular or tissue level rather than at the behavioral level.

Is There a Role for Biomarkers?

Definitely—this is a major unmet need that when robustly addressed could massively impact this field. A biomarker is an indicator of disease state¹¹⁸ that provides information on key molecular/cellular events that may be difficult to measure directly. Examples of biomarkers commonly used in clinical practice include plasma RNA levels in the setting of HIV infection and intraocular pressure in the setting of glaucoma. A good biomarker must be in the causal pathway of the disease process and fully capture the net effect of treatment on the clinical outcome.^{119,120} Biomarkers are particularly useful in phase II trials, for example, to probe biological activity of a proposed therapy or to inform the decision whether to proceed to phase III.¹¹⁹ A valid biomarker for a drug aiming to enhance stroke recovery could improve decision-making regarding timing, duration, frequency, or intensity with which treatment is prescribed for individual subjects and could generate an improved understanding as to how findings in rodents relate to findings in humans.¹²¹ There have been important advances in the study of biomarkers of stroke recovery in humans. Evidence suggests that the optimal choice of biomarker likely varies according to degree of injury and may differ across neural systems. Numerous candidate biomarkers have been proposed, including blood-based tests, measures of brain structure and injury, and functional neuroimaging measures.^{77,122,123} However, valid biomarkers of motor recovery after stroke in human, and the effects of drug targeting motor recovery, remain to be established.

How Do Current Systems of Care Affect the Study of Drugs to Enhance Motor Recovery After Stroke?

Current patterns of care delivery may be important in several regards. Concomitant experience and training are key factor when studying stroke recovery (see above). Provision of healthcare, including poststroke rehabilitation therapy, differs substantially across countries and insurance plans, and

should be considered in the design of restorative trials. Even in optimal settings, the dose of rehabilitation therapy may be lower than desired.¹²⁴ In the absence of approved therapies, clinicians prescribe unapproved drugs in the hopes that they can give patients some potential advantage, a fact that adds complexity to trials and so is worthy of note in the study of recovery-related drugs.¹²⁵ In many US healthcare systems, a patient may be transferred to several care settings, under the care of several different physicians, during the critical month of brain repair after stroke onset, a fact that can also complicate clinical trials in stroke recovery.

Are There Data That a Restorative Therapy Can Enhance Motor Outcome After Stroke in Humans, and Are Such Effects Clinically Meaningful?

Several key trials have described effects that readily meet the definition of clinically meaningful. The 9.7 point Fugl-Meyer motor scale score found with fluoxetine in the FLAME study²⁰ readily meets most definitions of minimum clinically important difference for this scale in patients recovering from stroke.¹²⁶ The same can be said for the 51.8% reduction in time to complete the Wolf Motor Function Test found 1 year after constraint-induced therapy in the Extremity Constraint-Induced Therapy Evaluation study,⁹¹ a prospective, single-blind, randomized clinical trial of 222 patients with arm motor deficits 3 to 9 months after stroke. Similarly, the Locomotor Experience Applied Post-Stroke trial⁹² found that 52% of enrollees receiving locomotor training shifted up an entire category of functional walking ability at 1 year after stroke, a remarkable therapeutic achievement.

Conclusions

In selected instances, solid evidence exists that a restorative therapy, introduced after injury is fixed, can improve behavioral outcome after stroke.¹²⁷ The largest trials to date have examined behavioral interventions, such as constraint-induced therapy or locomotor training. Regarding trials of drugs to enhance motor recovery, exciting results have been found in phase II studies of SSRIs and of L-Dopa. This review considered several factors important to stroke recovery trials.

Sources of Funding

This work was supported by National Institute of Health grants K24 HD074722 and 5M011 RR-00827.

Disclosures

Dr Cramer has served as a consultant for GlaxoSmithKline, MicroTransponder, Dart Neuroscience, Roche, and RAND Corporation.

References

1. Pardridge WM. Drug targeting to the brain. *Pharm Res*. 2007;24:1733–1744. doi: 10.1007/s11095-007-9324-2.
2. Cramer SC. An overview of therapies to promote repair of the brain after stroke. *Head Neck*. 2011;33(suppl 1):S5–S7. doi: 10.1002/hed.21840.
3. Rathore SS, Hinn AR, Cooper LS, Tyroler HA, Rosamond WD. Characterization of incident stroke signs and symptoms: findings from the atherosclerosis risk in communities study. *Stroke*. 2002;33:2718–2721.
4. Gresham G, Duncan P, Stason W, Adams H, Adelman A, Alexander D, et al. *Post-Stroke Rehabilitation*. Rockville, MD: US Department of Health

and Human Services. Public Health Service, Agency for Health Care Policy and Research; 1995.

5. Saposnik G, Levin M; Outcome Research Canada (SORCan) Working Group. Virtual reality in stroke rehabilitation: a meta-analysis and implications for clinicians. *Stroke*. 2011;42:1380–1386. doi: 10.1161/STROKEAHA.110.605451.
6. Winstein CJ, Wolf SL, Dromerick AW, Lane CJ, Nelsen MA, Lewthwaite R, et al; ICARE Investigative Team. Interdisciplinary Comprehensive Arm Rehabilitation Evaluation (ICARE): a randomized controlled trial protocol. *BMC Neurol*. 2013;13:5. doi: 10.1186/1471-2377-13-5.
7. Wyller TB, Sveen U, Sjørding KM, Pettersen AM, Bautz-Holter E. Subjective well-being one year after stroke. *Clin Rehabil*. 1997;11:139–145.
8. Stewart JC, Cramer SC. Patient-reported measures provide unique insights into motor function after stroke. *Stroke*. 2013;44:1111–1116. doi: 10.1161/STROKEAHA.111.674671.
9. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. *J Am Geriatr Soc*. 2006;54:743–749. doi: 10.1111/j.1532-5415.2006.00701.x.
10. Fritz S, Lusardi M. White paper: “walking speed: the sixth vital sign.” *J Geriatr Phys Ther*. 2009;32:46–49.
11. Miller EL, Murray L, Richards L, Zorowitz RD, Bakas T, Clark P, et al; American Heart Association Council on Cardiovascular Nursing and the Stroke Council. Comprehensive overview of nursing and interdisciplinary rehabilitation care of the stroke patient: a scientific statement from the American Heart Association. *Stroke*. 2010;41:2402–2448. doi: 10.1161/STR.0b013e3181e7512b.
12. Traynor K. Dalfampridine approved for MS. *Am J Health Syst Pharm*. 2010;67:335. doi: 10.2146/news100015.
13. Cools R, Roberts AC, Robbins TW. Serotonergic regulation of emotional and behavioural control processes. *Trends Cogn Sci*. 2008;12:31–40. doi: 10.1016/j.tics.2007.10.011.
14. Logue SF, Gould TJ. The neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition. *Pharmacol Biochem Behav*. 2014;123:45–54. doi: 10.1016/j.pbb.2013.08.007.
15. Cowen P, Sherwood AC. The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. *J Psychopharmacol*. 2013;27:575–583. doi: 10.1177/0269881113482531.
16. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, et al. Effects of fluoxetine and maprotiline on functional recovery in post-stroke hemiplegic patients undergoing rehabilitation therapy. *Stroke*. 1996;27:1211–1214.
17. Miyai I, Reding R. Effects of antidepressants on functional recovery following stroke. *J Neuro Rehab*. 1998;12:5–13.
18. Pariente J, Loubinoux I, Carel C, Albuher JF, Leger A, Manelfe C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. *Ann Neurol*. 2001;50:718–729.
19. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression—a three-month double-blind placebo-controlled study with an open-label long-term follow up. *J Neurol*. 2003;250:347–351. doi: 10.1007/s00415-003-1014-3.
20. Chollet F, Tardy J, Albuher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurol*. 2011;10:123–130. doi: 10.1016/S1474-4422(10)70314-8.
21. Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. *JAMA*. 2008;299:2391–2400. doi: 10.1001/jama.299.20.2391.
22. Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. *Arch Gen Psychiatry*. 2010;67:187–196. doi: 10.1001/archgenpsychiatry.2009.185.
23. Mikami K, Jorge RE, Moser DJ, Arndt S, Jang M, Solodkin A, et al. Prevention of post-stroke generalized anxiety disorder, using escitalopram or problem-solving therapy. *J Neuropsychiatry Clin Neurosci*. 2014;26:323–328. doi: 10.1176/appi.neuropsych.11020047.
24. Aarts N, Akoudad S, Noordam R, Hofman A, Ikram MA, Stricker BH, et al. Inhibition of serotonin reuptake by antidepressants and cerebral microbleeds in the general population. *Stroke*. 2014;45:1951–1957. doi: 10.1161/STROKEAHA.114.004990.
25. Hankey GJ. Selective serotonin reuptake inhibitors and risk of cerebral bleeding. *Stroke*. 2014;45:1917–1918. doi: 10.1161/STROKEAHA.114.005844.

26. Walker FR. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? *Neuropharmacology*. 2013;67:304–317. doi: 10.1016/j.neuropharm.2012.10.002.
27. Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. *J Affect Disord*. 1997;45:19–30.
28. Cukrowicz KC, Schlegel EF, Smith PN, Jacobs MP, Van Orden KA, Paukert AL, et al. Suicide ideation among college students evidencing subclinical depression. *J Am Coll Health*. 2011;59:575–581. doi: 10.1080/07448481.2010.483710.
29. da Rocha e Silva CE, Alves Brasil MA, Matos do Nascimento E, de Braganca Pereira B, Andre C. Is poststroke depression a major depression? *Cerebrovasc Dis*. 2013;35:385–391.
30. Spalletta G, Ripa A, Caltagirone C. Symptom profile of DSM-IV major and minor depressive disorders in first-ever stroke patients. *Am J Geriatr Psychiatry*. 2005;13:108–115. doi: 10.1176/appi.ajgp.13.2.108.
31. Saxena SK, Ng TP, Koh G, Yong D, Fong NP. Is improvement in impaired cognition and depressive symptoms in post-stroke patients associated with recovery in activities of daily living? *Acta Neurol Scand*. 2007;115:339–346. doi: 10.1111/j.1600-0404.2006.00751.x.
32. Maes M, Leonard B, Fernandez A, Kubera M, Nowak G, Veerhuis R, et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35:659–663. doi: 10.1016/j.pnpbp.2011.02.019.
33. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. *Biol Psychiatry*. 2006;59:1116–1127. doi: 10.1016/j.biopsych.2006.02.013.
34. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science*. 2003;301:805–809. doi: 10.1126/science.1083328.
35. Gerdelat-Mas A, Loubinoux I, Tombari D, Rascol O, Chollet F, Simonetta-Moreau M. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. *Neuroimage*. 2005;27:314–322. doi: 10.1016/j.neuroimage.2005.05.009.
36. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O’Leary OF, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. *Science*. 2008;320:385–388. doi: 10.1126/science.1150516.
37. Guirado R, Perez-Rando M, Sanchez-Matarredona D, Castrén E, Nacher J. Chronic fluoxetine treatment alters the structure, connectivity and plasticity of cortical interneurons. *Int J Neuropsychopharmacol*. 2014;17:1635–1646. doi: 10.1017/S1461145714000406.
38. Perrier JF, Cotel F. Serotonergic modulation of spinal motor control. *Curr Opin Neurobiol*. 2014;33C:1–7. doi: 10.1016/j.conb.2014.12.008.
39. Tritsch NX, Sabatini BL. Dopaminergic modulation of synaptic transmission in cortex and striatum. *Neuron*. 2012;76:33–50. doi: 10.1016/j.neuron.2012.09.023.
40. McAllister TW. Polymorphisms in genes modulating the dopamine system: do they influence outcome and response to medication after traumatic brain injury? *J Head Trauma Rehabil*. 2009;24:65–68. doi: 10.1097/HTR.0b013e31819966b.
41. Molina-Luna K, Pektanovic A, Röhrich S, Hertler B, Schubring-Giese M, Rioult-Pedotti MS, et al. Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. *PLoS One*. 2009;4:e7082. doi: 10.1371/journal.pone.0007082.
42. Hosp JA, Pektanovic A, Rioult-Pedotti MS, Luft AR. Dopaminergic projections from midbrain to primary motor cortex mediate motor skill learning. *J Neurosci*. 2011;31:2481–2487. doi: 10.1523/JNEUROSCI.5411-10.2011.
43. Scheidtmann K, Fries W, Müller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. *Lancet*. 2001;358:787–790. doi: 10.1016/S0140-6736(01)05966-9.
44. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. *Clin Neuropharmacol*. 1984;7:35–49.
45. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. *J Neurochem*. 1987;48:1077–1082.
46. Doshi PS, Edwards DJ. Effects of L-dopa on dopamine and norepinephrine concentrations in rat brain assessed by gas chromatography. *J Chromatogr*. 1981;210:505–511.
47. Everett GM, Borcharding JW. L-dopa: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. *Science*. 1970;168:849–850. doi: 10.1126/science.168.3933.849.
48. Small SL. Pharmacotherapy of aphasia. A critical review. *Stroke*. 1994;25:1282–1289.
49. Floel A, Hummel F, Breitenstein C, Knecht S, Cohen LG. Dopaminergic effects on encoding of a motor memory in chronic stroke. *Neurology*. 2005;65:472–474. doi: 10.1212/01.wnl.0000172340.56307.5e.
50. Cramer SC, Dobkin BH, Noser EA, Rodriguez RW, Enney LA. Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. *Stroke*. 2009;40:3034–3038. doi: 10.1161/STROKEAHA.109.552075.
51. Restemeyer C, Weiller C, Liepert J. No effect of a levodopa single dose on motor performance and motor excitability in chronic stroke. A double-blind placebo-controlled cross-over pilot study. *Restor Neurol Neurosci*. 2007;25:143–150.
52. Sonde L, Lökk J. Effects of amphetamine and/or L-dopa and physiotherapy after stroke—a blinded randomized study. *Acta Neurol Scand*. 2007;115:55–59. doi: 10.1111/j.1600-0404.2006.00728.x.
53. Pearson-Fuhrhop KM, Minton B, Acevedo D, Shahbaba B, Cramer SC. Genetic variation in the human brain dopamine system influences motor learning and its modulation by L-Dopa. *PLoS One*. 2013;8:e61197. doi: 10.1371/journal.pone.0061197.
54. Pearson-Fuhrhop KM, Dunn EC, Mortero S, Devan WJ, Falcone GJ, Lee P, et al. Dopamine genetic risk score predicts depressive symptoms in healthy adults and adults with depression. *PLoS One*. 2014;9:e93772. doi: 10.1371/journal.pone.0093772.
55. Pearson-Fuhrhop KM, Cramer SC. Pharmacogenetics of neural injury recovery. *Pharmacogenomics*. 2013;14:1635–1643. doi: 10.2217/pgs.13.152.
56. Sesack SR, Grace AA. Cortico-Basal Ganglia reward network: microcircuitry. *Neuropsychopharmacology*. 2010;35:27–47. doi: 10.1038/npp.2009.93.
57. Abe M, Schambra H, Wassermann EM, Luckenbaugh D, Schweighofer N, Cohen LG. Reward improves long-term retention of a motor memory through induction of offline memory gains. *Curr Biol*. 2011;21:557–562. doi: 10.1016/j.cub.2011.02.030.
58. Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. *Neuron*. 2012;76:470–485. doi: 10.1016/j.neuron.2012.10.021.
59. Costa RM. Plastic corticostriatal circuits for action learning: what’s dopamine got to do with it? *Ann NY Acad Sci*. 2007;1104:172–191. doi: 10.1196/annals.1390.015.
60. Surmeier DJ, Plotkin J, Shen W. Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. *Curr Opin Neurobiol*. 2009;19:621–628. doi: 10.1016/j.conb.2009.10.003.
61. Garland T Jr, Schutz H, Chappell MA, Keeney BK, Meek TH, Copes LE, et al. The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives. *J Exp Biol*. 2011;214(pt 2):206–229. doi: 10.1242/jeb.048397.
62. Merzenich MM, Van Vleet TM, Nahum M. Brain plasticity-based therapeutics. *Front Hum Neurosci*. 2014;8:385. doi: 10.3389/fnhum.2014.00385.
63. Beltran EJ, Papadopoulos CM, Tsai SY, Kartje GL, Wolf WA. Long-term motor improvement after stroke is enhanced by short-term treatment with the alpha-2 antagonist, atipamezole. *Brain Res*. 2010;1346:174–182. doi: 10.1016/j.brainres.2010.05.063.
64. Zittel S, Weiller C, Liepert J. Reboxetine improves motor function in chronic stroke. A pilot study. *J Neurol*. 2007;254:197–201. doi: 10.1007/s00415-006-0326-5.
65. Wang LE, Fink GR, Diekhoff S, Rehme AK, Eickhoff SB, Grefkes C. Noradrenergic enhancement improves motor network connectivity in stroke patients. *Ann Neurol*. 2011;69:375–388. doi: 10.1002/ana.22237.
66. Luria A. The restoration of motor functions after brain injury. In: Luria A, ed. *Restoration of Function After Brain Injury*. New York, NY: The Macmillan Company; 1963:78–116.
67. Whyte EM, Lenze EJ, Butters M, Skidmore E, Koenig K, Dew MA, et al. An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. *Cerebrovasc Dis*. 2008;26:317–321. doi: 10.1159/000149580.

68. Barrett KM, Brott TG, Brown RD Jr, Carter RE, Geske JR, Graff-Radford NR, et al; Mayo Acute Stroke Trial for Enhancing Recovery (MASTER) Study Group. Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase IIA clinical trial. *J Stroke Cerebrovasc Dis*. 2011;20:177–182. doi: 10.1016/j.jstrokecerebrovasdis.2010.12.009.
69. Berthier ML, Green C, Higuera C, Fernández I, Hinojosa J, Martín MC. A randomized, placebo-controlled study of donepezil in post-stroke aphasia. *Neurology*. 2006;67:1687–1689. doi: 10.1212/01.wnl.0000242626.69666.e2.
70. Crisostomo EA, Duncan PW, Propst M, Dawson DV, Davis JN. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. *Ann Neurol*. 1988;23:94–97. doi: 10.1002/ana.410230117.
71. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. *Stroke*. 1995;26:2254–2259.
72. Walker-Batson D, Curtis S, Natarajan R, Ford J, Dronkers N, Salmeron E, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. *Stroke*. 2001;32:2093–2098.
73. Gladstone DJ, Danells CJ, Armesto A, McIlroy WE, Staines WR, Graham SJ, et al; Subacute Therapy with Amphetamine and Rehabilitation for Stroke Study Investigators. Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. *Stroke*. 2006;37:179–185. doi: 10.1161/01.STR.0000195169.42447.78.
74. Walker-Batson D, Mehta J, Smith P, Johnson M. Amphetamine and other pharmacological agents in human and animal studies of recovery from stroke [published online ahead of print April 18, 2015]. *Prog Neuropsychopharmacol Biol Psychiatry*. doi: 10.1016/j.pnpbp.2015.04.002.
75. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. *Science*. 1982;217:855–857.
76. Goldstein LB. Common drugs may influence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators. *Neurology*. 1995;45:865–871.
77. Bütefisch CM, Davis BC, Wise SP, Sawaki L, Kopylev L, Classen J, et al. Mechanisms of use-dependent plasticity in the human motor cortex. *Proc Natl Acad Sci U S A*. 2000;97:3661–3665. doi: 10.1073/pnas.050350297.
78. Conroy B, Zorowitz R, Horn SD, Ryser DK, Teraoka J, Smout RJ. An exploration of central nervous system medication use and outcomes in stroke rehabilitation. *Arch Phys Med Rehabil*. 2005;86(12 suppl 2):S73–S81. doi: 10.1016/j.apmr.2005.08.129.
79. Cramer SC. Issues in clinical trial methodology for brain repair after stroke. In: Cramer SC, Nudo RJ, eds. *Brain Repair After Stroke*. Cambridge, UK: Cambridge University Press; 2010:173–182.
80. Overman JJ, Carmichael ST. Plasticity in the injured brain: more than molecules matter. *Neuroscientist*. 2014;20:15–28. doi: 10.1177/1073858413491146.
81. Cramer SC. Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery. *Ann Neurol*. 2008;63:272–287. doi: 10.1002/ana.21393.
82. Li S, Carmichael ST. Growth-associated gene and protein expression in the region of axonal sprouting in the aged brain after stroke. *Neurobiol Dis*. 2006;23:362–373. doi: 10.1016/j.nbd.2006.03.011.
83. Cramer SC, Chopp M. Recovery recapitulates ontogeny. *Trends Neurosci*. 2000;23:265–271.
84. Biernaskie J, Chernenko G, Corbett D. Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. *J Neurosci*. 2004;24:1245–1254. doi: 10.1523/JNEUROSCI.3834-03.2004.
85. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. *Stroke*. 2001;32:1005–1011.
86. Ren J, Kaplan PL, Charette MF, Speller H, Finklestein SP. Time window of intracisternal osteogenic protein-1 in enhancing functional recovery after stroke. *Neuropharmacology*. 2000;39:860–865.
87. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. *Neuropharmacology*. 2000;39:1483–1494.
88. Kozłowski DA, Jones TA, Schallert T. Pruning of dendrites and restoration of function after brain damage: role of the NMDA receptor. *Restor Neurol Neurosci*. 1994;7:119–126. doi: 10.3233/RNN-1994-7207.
89. Narasimhan P, Liu J, Song YS, Massengale JL, Chan PH. VEGF stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral endothelial cells after ischemic conditions. *Stroke*. 2009;40:1467–1473. doi: 10.1161/STROKEAHA.108.534644.
90. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. *Stroke*. 2007;38(2 suppl):748–752. doi: 10.1161/01.STR.0000253500.32979.d1.
91. Wolf SL, Winstein CJ, Miller JP, Taub E, Uswatte G, Morris D, et al; EXCITE Investigators. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. *JAMA*. 2006;296:2095–2104. doi: 10.1001/jama.296.17.2095.
92. Duncan PW, Sullivan KJ, Behrman AL, Azen SP, Wu SS, Nadeau SE, et al; LEAPS Investigative Team. Body-weight-supported treadmill rehabilitation after stroke. *N Engl J Med*. 2011;364:2026–2036. doi: 10.1056/NEJMoa1010790.
93. García-Alfás G, Barkhuysen S, Buckle M, Fawcett JW. Chondroitinase ABC treatment opens a window of opportunity for task-specific rehabilitation. *Nat Neurosci*. 2009;12:1145–1151. doi: 10.1038/nn.2377.
94. Cramer SC, Sur M, Dobkin BH, O'Brien C, Sanger TD, Trojanowski JQ, et al. Harnessing neuroplasticity for clinical applications. *Brain*. 2011;134(pt 6):1591–1609. doi: 10.1093/brain/awr039.
95. Fang PC, Barbay S, Plautz EJ, Hoover E, Strittmatter SM, Nudo RJ. Combination of NEP 1-40 treatment and motor training enhances behavioral recovery after a focal cortical infarct in rats. *Stroke*. 2010;41:544–549. doi: 10.1161/STROKEAHA.109.572073.
96. Starkey ML, Schwab ME. Anti-Nogo-A and training: can one plus one equal three? *Exp Neurol*. 2012;235:53–61. doi: 10.1016/j.expneurol.2011.04.008.
97. Hovda DA, Fenney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. *Brain Res*. 1984;298:358–361.
98. Adkins-Muir DL, Jones TA. Cortical electrical stimulation combined with rehabilitative training: enhanced functional recovery and dendritic plasticity following focal cortical ischemia in rats. *Neurol Res*. 2003;25:780–788. doi: 10.1179/016164103771953853.
99. Adkins DL, Hsu JE, Jones TA. Motor cortical stimulation promotes synaptic plasticity and behavioral improvements following sensorimotor cortex lesions. *Exp Neurol*. 2008;212:14–28. doi: 10.1016/j.expneurol.2008.01.031.
100. Johansson BB. Brain plasticity and stroke rehabilitation. The Willis lecture. *Stroke*. 2000;31:223–230.
101. Riley JD, Le V, Der-Yeghiaian L, See J, Newton JM, Ward NS, et al. Anatomy of stroke injury predicts gains from therapy. *Stroke*. 2011;42:421–426. doi: 10.1161/STROKEAHA.110.599340.
102. Stinear CM, Barber PA, Petoe M, Anwar S, Byblow WD. The PREP algorithm predicts potential for upper limb recovery after stroke. *Brain*. 2012;135(pt 8):2527–2535. doi: 10.1093/brain/awr146.
103. Burke Quinlan E, Dodakian L, See J, McKenzie A, Le V, Wojnowicz M, et al. Neural function, injury, and stroke subtype predict treatment gains after stroke. *Ann Neurol*. 2015;77:132–145. doi: 10.1002/ana.24309.
104. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. *Mol Psychiatry*. 2010;15:473–500. doi: 10.1038/mp.2008.116.
105. Kohen R, Cain KC, Buzaitis A, Johnson V, Becker KJ, Teri L, et al. Response to psychosocial treatment in poststroke depression is associated with serotonin transporter polymorphisms. *Stroke*. 2011;42:2068–2070.
106. Kleim JA, Bruneau R, VandenBerg P, MacDonald E, Mulrooney R, Pockock D. Motor cortex stimulation enhances motor recovery and reduces peri-infarct dysfunction following ischemic insult. *Neurol Res*. 2003;25:789–793. doi: 10.1179/016164103771953862.
107. Plautz EJ, Barbay S, Frost SB, Friel KM, Dancause N, Zoubina EV, et al. Post-infarct cortical plasticity and behavioral recovery using concurrent cortical stimulation and rehabilitative training: a feasibility study in primates. *Neurol Res*. 2003;25:801–810. doi: 10.1179/016164103771953880.
108. Teskey GC, Flynn C, Goertzen CD, Monfils MH, Young NA. Cortical stimulation improves skilled forelimb use following a focal ischemic infarct in the rat. *Neurol Res*. 2003;25:794–800. doi: 10.1179/016164103771953871.
109. Levy RM, Harvey RL, Kissela BM, Winstein CJ, Lutsep HL, Parrish TB, et al. Epidural electrical stimulation for stroke rehabilitation: results of the prospective, multicenter, randomized, single-blinded everest trial [published online ahead of print March 6, 2015]. *Neurorehabil Neural Repair*. pii: 1545968315575613.
110. Nouri S, Cramer SC. Anatomy and physiology predict response to motor cortex stimulation after stroke. *Neurology*. 2011;77:1076–1083. doi: 10.1212/WNL.0b013e31822e1482.

111. Cramer SC, Koroshetz WJ, Finklestein SP. The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agents. *Stroke*. 2007;38:1393–1395. doi: 10.1161/01.STR.0000260087.67462.80.
112. Salbach NM, Mayo NE, Higgins J, Ahmed S, Finch LE, Richards CL. Responsiveness and predictability of gait speed and other disability measures in acute stroke. *Arch Phys Med Rehabil*. 2001;82:1204–1212. doi: 10.1053/apmr.2001.24907.
113. Perry J, Garrett M, Gronley JK, Mulroy SJ. Classification of walking handicap in the stroke population. *Stroke*. 1995;26:982–989.
114. Prasad A, Kumar SS, Dessimoz C, Bleuler S, Laule O, Hruz T, et al. Global regulatory architecture of human, mouse and rat tissue transcriptomes. *BMC Genomics*. 2013;14:716. doi: 10.1186/1471-2164-14-716.
115. Chan ET, Quon GT, Chua G, Babak T, Trochesset M, Zirngibl RA, et al. Conservation of core gene expression in vertebrate tissues. *J Biol*. 2009;8:33. doi: 10.1186/jbiol130.
116. Cramer SC. Repairing the human brain after stroke. II. Restorative therapies. *Ann Neurol*. 2008;63:549–560. doi: 10.1002/ana.21412.
117. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for industry. Clinical studies section of labeling for human prescription drug and biological products—content and format. <http://www.Fda.Gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm075059.Pdf>. Published January 2006. Accessed July 11, 2015.
118. Temple R. A regulatory authority's opinion about surrogate endpoints. In: Nimmo W, Tucker G, eds. *Clinical Measurement in Drug Evaluation*. New York: J. Wiley; 1995:3–22.
119. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? *Ann Intern Med*. 1996;125:605–613.
120. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. *JAMA*. 1999;282:771–778.
121. Dijkhuizen RM, van der Marel K, Otte WM, Hoff EI, van der Zijden JP, van der Toorn A, et al. Functional MRI and diffusion tensor imaging of brain reorganization after experimental stroke. *Transl Stroke Res*. 2012;3:36–43. doi: 10.1007/s12975-011-0143-8.
122. Tardy J, Pariente J, Leger A, Dechaumont-Palacin S, Gerdelat A, Guiraud V, et al. Methylphenidate modulates cerebral post-stroke reorganization. *Neuroimage*. 2006;33:913–922. doi: 10.1016/j.neuroimage.2006.07.014.
123. Burke E, Cramer SC. Biomarkers and predictors of restorative therapy effects after stroke. *Curr Neurol Neurosci Rep*. 2013;13:329. doi: 10.1007/s11910-012-0329-9.
124. Lang CE, Macdonald JR, Reisman DS, Boyd L, Jacobson Kimberley T, Schindler-Ivens SM, et al. Observation of amounts of movement practice provided during stroke rehabilitation. *Arch Phys Med Rehabil*. 2009;90:1692–1698. doi: 10.1016/j.apmr.2009.04.005.
125. Zorowitz RD, Smout RJ, Gassaway JA, Horn SD. Neurostimulant medication usage during stroke rehabilitation: the Post-Stroke Rehabilitation Outcomes Project (PSROP). *Top Stroke Rehabil*. 2005;12:28–36. doi: 10.1310/2403-B0CY-1UDN-4B6D.
126. See J, Dodakian L, Chou C, Chan V, McKenzie A, Reinkensmeyer DJ, et al. A standardized approach to the Fugl-Meyer assessment and its implications for clinical trials. *Neurorehabil Neural Repair*. 2013;27:732–741. doi: 10.1177/1545968313491000.
127. Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. *Lancet Neurol*. 2012;11:369–380. doi: 10.1016/S1474-4422(12)70039-X.

KEY WORDS: drugs ■ motor system ■ outcomes ■ recovery ■ stroke